N/A N=160 Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer
Diabetic Foot Ulcer
Primary: Demographic Characteristics: Weight (Mean) — 73.7; 78.3 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=718 AVANCE-Houston Building Futures Program Evaluation
Youth
Primary: Healthy Partner Relationship Behavior Measurement #1 — 2.96; 2.93 score on a scale
N/A N=26 SimpleC Wellness Platform With Social Robot Interaction
Engagement, Patient · Mood · Quality of Life
Primary: Facilitators to Successful Implementation — 33; 30; 24; 27 Total number of mentions
Phase 3 N=69 Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Pharmacokinetics · Pharmacodynamics
Primary: Maximum Serum Insulin Aspart Concentration, CIAmax — 2961.8; 2827.4 pg/mL
Phase 4 N=25 Preventing Recurrent UTI With Vaginal Estrogen
Recurrent Urinary Tract Infection · Urinary Tract Infections · Cystitis Recurrent
Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance
N/A N=72 A Peer-Delivered High School Preparatory Intervention for Students With ADHD
ADHD
Primary: Grade Point Average — 2.62; 2.39; 2.60; 2.55 grade point average — p=.260
N/A N=33 Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide
Type 1 Diabetes
Primary: Incremental Area Under the Curve of Postprandial Glucose Following the First Meal — 18.1; 20.9 (mg/dl*min)/1000 — p=0.017
N/A N=39 Project Engage: A Wrist Biosensor-based mHealth Suite to Support Alcohol Intervention in Young People Living With HIV
HIV
Primary: Engagement in Biosensor Wearing — 20.6; 25.0 percentage of time worn — p=0.698
N/A N=9 Behavioral Economics and Communication
Problem Behavior
Primary: Averge of Aappropriate Communication Responses — 3.33 direct observation of 5-min sessions
N/A N=150 Light Therapy for PD - Dose Selection
Parkinson Disease · Sleep Disorder · Fatigue
Primary: Parkinson's Disease Sleep Scale 2 — -1.5202; -2.5692; -0.408; -1.7608 score on a scale
N/A N=725 The Russian Multicenter Observational Study "Evaluation of the HDQ for the Diagnosis of Hemorrhoidal Disease ( HDQ )
Haemorrhoids
Primary: Sensitivity of the HDQ for Screening — 627 Participants
Phase 2 N=856 A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
Alzheimer's Disease
Primary: Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12 — 0.113; 0.134; 0.119; 0.116 score on a scale
Early Phase 1 N=16 Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study
Aging · Arterial Stiffness · Endothelial Dysfunction
Primary: Change in Carotid Artery Compliance in mm/mmHg x 10-1 — 0.88; 0.87; 0.90; 0.79 mm/mmHg x 10-1
Phase 2 N=11 A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Prostate Adenocarcinoma
Primary: 6-Month Radiographic Progression-Free Survival (rPFS6) — 6 Participants — p=0.006
Phase 3 N=54 A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Lung Diseases, Interstitial
Primary: Number of Patients With Treatment-emergent Adverse Events (AEs) Over the Whole Trial — 53 Participants